Suppr超能文献

相似文献

2
Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.
Bioorg Med Chem. 2009 May 15;17(10):3733-8. doi: 10.1016/j.bmc.2009.03.034. Epub 2009 Mar 25.
3
New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
J Med Chem. 2011 Jul 28;54(14):5205-20. doi: 10.1021/jm2004738. Epub 2011 Jun 28.
4
Exploring C2 and N Substituent Effects on Truncated 4'-Thioadenosine Derivatives as Dual A and A Adenosine Receptor Ligands.
ChemMedChem. 2025 Feb 16;20(4):e202400575. doi: 10.1002/cmdc.202400575. Epub 2024 Nov 21.
9
Steric influence of 4'-position substituents and C2-Hexynyl group on AAR antagonism in truncated 4'-Thioadenosine derivatives.
Bioorg Chem. 2025 Jun 1;159:108359. doi: 10.1016/j.bioorg.2025.108359. Epub 2025 Mar 12.

引用本文的文献

1
Structure-Activity Relationship Analysis of 2-Aryl-8-alkynyl Adenine and Nucleoside Scaffolds as A Adenosine Receptor Ligands.
ACS Med Chem Lett. 2025 Apr 2;16(5):880-886. doi: 10.1021/acsmedchemlett.5c00138. eCollection 2025 May 8.
2
Synthesis and Modification of Cordycepin-Phosphoramidate ProTide Derivatives for Antiviral Activity and Metabolic Stability.
ACS Bio Med Chem Au. 2024 Dec 7;5(1):89-105. doi: 10.1021/acsbiomedchemau.4c00071. eCollection 2025 Feb 19.
5
New paradigms in purinergic receptor ligand discovery.
Neuropharmacology. 2023 Jun 1;230:109503. doi: 10.1016/j.neuropharm.2023.109503. Epub 2023 Mar 13.
6
Anti-obesity effects of the dual-active adenosine A/A receptor-ligand LJ-4378.
Int J Obes (Lond). 2022 Dec;46(12):2128-2136. doi: 10.1038/s41366-022-01224-x. Epub 2022 Sep 27.
7
GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A Adenosine Receptor.
J Med Chem. 2022 Sep 8;65(17):11648-11657. doi: 10.1021/acs.jmedchem.2c00462. Epub 2022 Aug 17.
8
Targeting purinergic receptors to attenuate inflammation of dry eye.
Purinergic Signal. 2023 Mar;19(1):199-206. doi: 10.1007/s11302-022-09851-9. Epub 2022 Feb 26.
10
Adenosine receptors as promising targets for the management of ocular diseases.
Med Chem Res. 2021;30(2):353-370. doi: 10.1007/s00044-021-02704-x. Epub 2021 Jan 25.

本文引用的文献

1
GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists.
Bioconjug Chem. 2011 Jun 15;22(6):1115-27. doi: 10.1021/bc1005812. Epub 2011 May 12.
3
Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species.
Exp Eye Res. 2010 Jan;90(1):146-54. doi: 10.1016/j.exer.2009.10.001. Epub 2009 Oct 28.
4
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.
Science. 2008 Nov 21;322(5905):1211-7. doi: 10.1126/science.1164772. Epub 2008 Oct 2.
7
The Sonogashira reaction: a booming methodology in synthetic organic chemistry.
Chem Rev. 2007 Mar;107(3):874-922. doi: 10.1021/cr050992x. Epub 2007 Feb 17.
8
Adenosine receptors as therapeutic targets.
Nat Rev Drug Discov. 2006 Mar;5(3):247-64. doi: 10.1038/nrd1983.
10
Carbon-carbon bonding made easy.
Chem Commun (Camb). 2005 Oct 14(38):4759-63. doi: 10.1039/b507375h. Epub 2005 Sep 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验